



Hepatocellular Carcinoma: From Molecular Mechanisms to Novel Therapeutic Approaches

Guest Editor:

Prof. Dr. Joon Hyuk Choi

Department of Pathology,
College of Medicine, Yeungnam
University, Gyeongsan, Korea

Deadline for manuscript
submissions:

closed (15 November 2023)

Message from the Guest Editor

Dear Colleagues,

This Special Issue, “Hepatocellular Carcinoma: From Basic Research to Novel Therapeutic Approaches,” will focus on molecular findings, pathology, biomarkers, diagnostic imaging, clinical features, and novel therapeutic approaches relating to hepatocellular carcinoma (HCC).

HCC is the fourth leading cause of cancer-related death worldwide. It is a highly heterogeneous tumor at the molecular and pathological levels, and its incidence is increasing in Western countries. In the past decade, novel molecular findings, pathogenic mechanisms, and therapeutic targets have improved our understanding of HCC. Despite advances in many areas, the molecular pathogenesis of HCC has not been fully elucidated. The accurate diagnosis of HCC and therapeutic strategies remain challenging.

This Special Issue is open to basic and clinical research on HCC, as well as multidisciplinary approaches, and will cover original articles and reviews on the following topics: hepatocellular carcinoma, primary liver cancer, molecular biology, carcinogenesis, precancerous conditions, subtypes, biomarkers, diagnostic imaging, and novel therapeutic approaches.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)